Alder Biopharmaceuticals is bringing new therapies to the treatment of migraine, rheumatoid arthritis, and other conditions.

 

Efficacy and safety data from a Phase IIb dose-ranging study of subcutaneous Clazakizumab in adults with moderate-to-severe rheumatoid arthritis presented at ACR 2013. Read the story.


Alder wins 2013 Innovation in Biopharmaceuticals Award from Seattle Business Magazine. Read the story.


 
Fact
Clazakizumab is a humanized monoclonal antibody, discovered by Alder, which binds to and inhibits IL-6. IL-6 is an important driver of the inflammatory response and is implicated in the transition from acute to chronic inflammation.
Fact
Rheumatoid arthritis is a chronic inflammatory disorder that principally attacks joints. Approximately 2.4 million patients, predominantly women, suffer from RA in the United States.
Fact
ALD403 is a monoclonal antibody, discovered by Alder, which targets CGRP for prevention of migraine. CGRP is a small protein that is involved in the transmission and heightened sensitivity to pain experienced in migraine.
Fact
According to the American Migraine Foundation, migraine is three times more common in women than men and migraine affects 30% of women over a lifetime.
Fact
According to a 2012 report by the U.S. Agency for Healthcare Research and Quality, headaches accounted for 2.1 million visits to the emergency room annually.
Fact
For the 12.6 million U.S. migraine patients who are candidates for migraine prevention, there are few therapeutic options to manage their disease.
Fact
The Migraine Research Foundation estimates U.S. employers lose more than US$13 billion each year as a result of 113 million lost workdays due to migraine.
Fact
Migraine is a significant cause of disability, generally affecting individuals between the ages of 20 and 50, their prime working years.
Fact
Approximately 36 million Americans suffer from migraines, but only 20 million migraine sufferers have been clinically diagnosed.